EP0200280A3
Oxidation resistant il-2 muteins and their production, formulations containing such muteins, and dna sequences and expression vectors coding for such muteins and corresponding transformed host cells
Abstract
A biologically active reference (e.g. human) IL-2 (interleukin-2) protein is protected against oxidation by a method involving substituting a conservative amino acid for each methionine residue susceptible to chloramine T or peroxide oxidation and wherein additional, non-susceptible methionine residues are not so substituted.
Term
Term ended
Projected expiry passed 17 January 2006, 20.7 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
Every citation, both waysCites: the store holds 3 of 4
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| EP0130756B1 | Cites | European Patent Office (EPO) | YD | Search report |
| EP0163249A2 | Cites | European Patent Office (EPO) | Y | Search report |
| WO8500817A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report |
| NATURE, vol. 312, 1st November 1984, pages 77-80, New York, US; S. ROSENBERG et al.: "Synthesis in yeast of a functional oxidation-resistant mutant of human alpha1-antitrypsin" | Non-patent | – | – | Search report |
| CELLULAR AND MOLECULAR BIOLOGY OF LYMPHOKINES, 1985, pages 595-603, Academic Press, Inc.; W. FIERS et al.: "Cloning, characterization and expression of human and mouse lymphokine genes (interferon-gamma and interleukin-2)" | Non-patent | – | – | Search report |
16 members in 8 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 692596 | United States of America | – | |
| 69259685 | United States of America | A | |
| 810656 | United States of America | – | |
| 81065685 | United States of America | A | |
| 692596 | – | – | – |
| 810656 | – | – | – |
| EP86300333 | – | – | – |
| US19850692596 | – | – | – |
| US19850810656 | – | – | – |
Members16
| Document | Office | Kind | |
|---|---|---|---|
| AU5245186A | Australia | A | |
| JPS61224985A | Japan | A | |
| EP0200280A2 | European Patent Office (EPO) | A2 | |
| AU6484686A | Australia | A | |
| US4752585A | United States of America | A | |
| EP0200280A3This record | European Patent Office (EPO) | A3 | |
| AU585084B2 | Australia | B2 | |
| NZ214854A | New Zealand | A | |
| US5116943A | United States of America | A | |
| EP0200280B1 | European Patent Office (EPO) | B1 | |
| AT85810T | Austria | T | |
| ATE85810T1 | Austria | T1 | |
| DE3687763D1 | Germany | D1 | |
| DE3687763T2 | Germany | T2 | |
| JP2595206B2 | Japan | B2 | |
| CA1340265C | Canada | C |
42 legal events, as 4 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Nl: ceased due to reaching the maximum lifetime of a patentCeasedNLV7 | NLV7 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| European patent in force as of 2002-01-01IF02 | IF02 | GB | |
| New agentNV | NV | CH | |
| Name/firm changedCETUS ONCOLOGY CORPORATION TRANSFER- CHIRON CORPORATIONPFA | PFA | CH | |
| Transmission of propertyTP | TP | FR | |
| Nl: assignments of ep-patentsNLS | NLS | EP | |
| Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)732E | 732E | GB | |
| Se: european patent in force in swedenEAL | EAL | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| Lu: last paid annual feeEPTA | EPTA | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Fr: translation filedET | ET | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0200280
- Publication, DOCDB
- 0200280
- Publication, EPODOC
- EP0200280
- Application
- 86200766
- Application, DOCDB
- 86200766
- Application, EPODOC
- EP19860200766
Titles3
- English
- OXIDATION RESISTANT IL-2 MUTEINS AND THEIR PRODUCTION, FORMULATIONS CONTAINING SUCH MUTEINS, AND DNA SEQUENCES AND EXPRESSION VECTORS CODING FOR SUCH MUTEINS AND CORRESPONDING TRANSFORMED HOST CELLS
- French
- IL-2 mutéines résistantes à l'oxydation et leur production, compositions contenant ces mutéines, séquences d'ADN et vecteurs d'expression codant pour ces mutéines et cellules hôtes correspondantes transformées
- German
- Oxidationsbeständige IL-2-Muteine und ihre Herstellung, diese Muteine enthaltende Zusammensetzungen, solche Muteine kodierende DNS-Sequenzen und Expressionsvektoren und korrespondierende transformierte Wirtzellen
Classification
- CPC, 1
- C07K14/55
- IPC, 15
- C12N15 09
- C07G99 00
- C07H21 04
- C07K14 55
- C12N1 16
- C12N1 18
- C12N1 20
- C12N9 00
- C12N15 00
- C12N15 26
- C12P21 00
- C12P21 02
- C12R1 19
- C12R1 865
- C12R1 91
Designated states1
- Contracting states, 1
- Sweden